These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 36009006)
1. Design, Synthesis and Pharmacological Evaluation of Novel Conformationally Restricted da Silva Cunha TT; Silva RR; Rodrigues DA; de Sena Murteira Pinheiro P; Kronenberger T; Sant'Anna CMR; Noël F; Fraga CAM Biomolecules; 2022 Aug; 12(8):. PubMed ID: 36009006 [TBL] [Abstract][Full Text] [Related]
2. Synthesis, in silico, and in vitro studies of novel dopamine D Elek M; Djokovic N; Frank A; Oljacic S; Zivkovic A; Nikolic K; Stark H Arch Pharm (Weinheim); 2021 Jun; 354(6):e2000486. PubMed ID: 33615541 [TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of bitopic arylpiperazine-hexahydro-pyrazinoquinolines as preferential dopamine D3 receptor ligands. Zhou B; Ji M; Cai J Bioorg Chem; 2018 Apr; 77():125-135. PubMed ID: 29353729 [TBL] [Abstract][Full Text] [Related]
4. Synthesis and evaluation of C9 alkoxy analogues of (-)-stepholidine as dopamine receptor ligands. Madapa S; Gadhiya S; Kurtzman T; Alberts IL; Ramsey S; Reith M; Harding WW Eur J Med Chem; 2017 Jan; 125():255-268. PubMed ID: 27688181 [TBL] [Abstract][Full Text] [Related]
5. Targeting the dopamine D3 receptor: an overview of drug design strategies. Cortés A; Moreno E; Rodríguez-Ruiz M; Canela EI; Casadó V Expert Opin Drug Discov; 2016 Jul; 11(7):641-64. PubMed ID: 27135354 [TBL] [Abstract][Full Text] [Related]
6. Design and Synthesis of Conformationally Flexible Scaffold as Bitopic Ligands for Potent D Kim HY; Lee JY; Hsieh CJ; Taylor M; Luedtke RR; Mach RH Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613875 [TBL] [Abstract][Full Text] [Related]
7. Synthesis, pharmacological evaluation and molecular modeling studies of triazole containing dopamine D3 receptor ligands. Peng X; Wang Q; Mishra Y; Xu J; Reichert DE; Malik M; Taylor M; Luedtke RR; Mach RH Bioorg Med Chem Lett; 2015 Feb; 25(3):519-23. PubMed ID: 25556097 [TBL] [Abstract][Full Text] [Related]
8. Analogues of Arylamide Phenylpiperazine Ligands To Investigate the Factors Influencing D3 Dopamine Receptor Bitropic Binding and Receptor Subtype Selectivity. Hayatshahi HS; Xu K; Griffin SA; Taylor M; Mach RH; Liu J; Luedtke RR ACS Chem Neurosci; 2018 Dec; 9(12):2972-2983. PubMed ID: 30010318 [TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of arylpiperazine-reverse amides as biased dopamine D3 receptor ligands. Cao Y; Paudel S; Zhang X; Kim KM; Cheon SH Bioorg Med Chem; 2015 Sep; 23(17):5264-72. PubMed ID: 26278029 [TBL] [Abstract][Full Text] [Related]
10. A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194. Audinot V; Newman-Tancredi A; Gobert A; Rivet JM; Brocco M; Lejeune F; Gluck L; Desposte I; Bervoets K; Dekeyne A; Millan MJ J Pharmacol Exp Ther; 1998 Oct; 287(1):187-97. PubMed ID: 9765337 [TBL] [Abstract][Full Text] [Related]
12. Comparison of the binding and functional properties of two structurally different D2 dopamine receptor subtype selective compounds. Luedtke RR; Mishra Y; Wang Q; Griffin SA; Bell-Horner C; Taylor M; Vangveravong S; Dillon GH; Huang RQ; Reichert DE; Mach RH ACS Chem Neurosci; 2012 Dec; 3(12):1050-62. PubMed ID: 23259040 [TBL] [Abstract][Full Text] [Related]
13. Exploring the structural basis and atomistic binding mechanistic of the selective antagonist blockade at D Appiah-Kubi P; Olotu FA; Soliman MES J Mol Recognit; 2021 May; 34(5):e2885. PubMed ID: 33401335 [TBL] [Abstract][Full Text] [Related]
14. Synthesis and structure-activity relationships of naphthamides as dopamine D3 receptor ligands. Huang Y; Luedtke RR; Freeman RA; Wu L; Mach RH J Med Chem; 2001 May; 44(11):1815-26. PubMed ID: 11356115 [TBL] [Abstract][Full Text] [Related]
15. Current drug treatments targeting dopamine D3 receptor. Leggio GM; Bucolo C; Platania CB; Salomone S; Drago F Pharmacol Ther; 2016 Sep; 165():164-77. PubMed ID: 27343365 [TBL] [Abstract][Full Text] [Related]
16. Challenges in the development of dopamine D2- and D3-selective radiotracers for PET imaging studies. Mach RH; Luedtke RR J Labelled Comp Radiopharm; 2018 Mar; 61(3):291-298. PubMed ID: 28857231 [TBL] [Abstract][Full Text] [Related]
17. A single glycine in extracellular loop 1 is the critical determinant for pharmacological specificity of dopamine D2 and D3 receptors. Michino M; Donthamsetti P; Beuming T; Banala A; Duan L; Roux T; Han Y; Trinquet E; Newman AH; Javitch JA; Shi L Mol Pharmacol; 2013 Dec; 84(6):854-64. PubMed ID: 24061855 [TBL] [Abstract][Full Text] [Related]
18. Selectivity of probes for PET imaging of dopamine D3 receptors. Doot RK; Dubroff JG; Labban KJ; Mach RH Neurosci Lett; 2019 Jan; 691():18-25. PubMed ID: 29518538 [TBL] [Abstract][Full Text] [Related]
19. Iodinated 2-aminotetralins and 3-amino-1-benzopyrans: ligands for dopamine D2 and D3 receptors. Chumpradit S; Kung MP; Vessotskie J; Foulon C; Mu M; Kung HF J Med Chem; 1994 Nov; 37(24):4245-50. PubMed ID: 7990123 [TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological evaluation of structurally constrained hybrid analogues containing ropinirole moiety as a novel class of potent and selective dopamine D3 receptor ligands. Zhou B; Hong KH; Ji M; Cai J Chem Biol Drug Des; 2018 Sep; 92(3):1597-1609. PubMed ID: 29710404 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]